← All trials
NCT04342325
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- Jan 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- Apr 13, 2020
- Last posted
- Apr 13, 2020
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nagoya UniversityLead sponsor
- Nagoya UniversityStudy chair
- Nagoya UniversityReponsible party - principal investigator
- Rohto Pharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.